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Introduction
Human urotensin-II (U-II) is a cyclic peptide of 11 amino acids, with a molecular weight of ~1,388 ( 1 ). U-II has been identified as an endogenous ligand for G-protein coupled receptor 14 (GPR14), which is now known as UT receptor ( 2 ) . Both U-II and UT receptor are expressed in different tissues, including the cardiovasculature, brain, kidney, atherosclerotic plaques in the coronary and carotid arteries, and abdominal aortic aneurysms ( 1 -4 ) . U-II is the most potent vasoconstrictor identified to date, with a potency 1-2 orders of magnitude greater than that of endothelin-1 (ET-1), and U-II has been shown to play an important role in the pathogenesis of pulmonary artery hypertension and remodeling ( 5 -7 ). The main sources of circulating U-II are thought to be the heart, liver, kidney, vascular endothelium, and lymphocytes ( 1 , 4 , 8 ) . Plasma concentrations of U-II average from 2 to 20 pmol/l in healthy volunteers ( 9 ) , and are increased in hypertension ( 10 ), atherosclerosis ( 11 ) , coronary artery disease ( 12 ) , congestive heart failure ( 13) , diabetes mellitus (14) , renal failure (15) , and portal hypertension caused by liver cirrhosis (16) . Cheung et al. (10) and we (11) reported that U-II is positively correlated with systolic blood pressure and has an etiological role in systemic hypertension and its complications. In addition, increased urinary excretion of U-II has been demonstrated in patients with essential hypertension (17) .
Oxidized low-density lipoprotein (ox-LDL) is a well-established risk factor for atherosclerosis, and stimulates the differentiation and proliferation of vascular smooth muscle cells (VSMCs). In particular, mildly oxidized LDL (mox-LDL) interacting with vasoactive agents and growth factors present in the vasculature may play an important role in the development of atherosclerosis, hypertension, and restenosis after angioplasty (18, 19) . Recently, we showed that the mitogenic effect of mox-LDL is mediated by its oxidative components, such as reactive oxygen species (ROS), lysophosphatidylcholine (LPC), and 4-hydroxy-2-nonenal (HNE) (19) (20) (21) (22) . These compounds in combination with U-II synergistically promote the induction of DNA synthesis in VSMCs (23) . In recent years, there has been renewal of interest in vasoactive oxidant hydrogen peroxide (H2O2) as a risk factor for hypertension and atherosclerosis (24) .
In the present study, we investigated the interactions between U-II and mox-LDL in comparison with those between other vasoconstrictor G-protein agonists (ET-1, angiotensin-II [Ang-II], 5-HT, thrombaxane-A2 [TX-A2]) and mox-LDL or H2O2 in inducing VSMC proliferation. In the present study, VSMC proliferation was examined by increases in both DNA synthesis and cell number. To elucidate the underlying mechanisms responsible for the synergistic interactions, we assessed the interactions between mitogenic mediators of mox-LDL (H2O2, LPC, HNE) and U-II, and their intracellular signal transduction pathways in inducing VSMC proliferation.
Methods
Materials
Human U-II, ET-1, Ang-II, 5-HT, LDL, LPC, H2O2, anti-Gq/ 11α antibody, GDP-β-S, erbstatin A, radicicol, Ro31-8220, PD98059, SP600125, Y27632, catalase, N-acetylcysteine (NAC), probucol, and diphenylene iodonium (DPI) were purchased from Sigma Chemical Co. (St. Louis, USA). HNE was purchased from Cayman Chemical Co. (Ann Arbor, USA). U46619 (TX-A2 mimic) was a generous gift from Upjohn Co. (Kalamazoo, USA). [ 3 H]Thymidine (specific activity, 20 Ci/ mol) was obtained from DuPont-NEN Research Products (Boston, USA).
LDL Oxidation
LDL was oxidized with CuSO4 at a final concentration of 5 μmol/l at 37°C, and the contents of thiobarbituric acid-reactive substances (TBARS) were determined every 30 min by sampling aliquots as described previously (19, 22) . Electrophoretic mobilities of all samples were examined by 1% agarose gel electrophoresis. The conditions that did not alter the electrophoretic mobility but increased TBARS contents were selected for preparation of mox-LDL. To obtain ox-LDL, LDL was oxidized at 37°C for 30 h followed by termination of oxidation with ethylenediamine tetraacetic acid (EDTA). Lipoprotein concentrations are expressed as protein concentrations. Even at a concentration of 10 mg/ml, native LDL showed no development of TBARS, whereas mox-LDL showed a slight increase in TBARS formation (2-4 nmol/mg protein), with no change in the electrophoretic mobility. In contrast, ox-LDL showed a significant increase in TBARS formation (35 nmol/mg protein) and an increase in electrophoretic mobility.
Cell Culture
VSMCs were isolated from the thoracic aortas of male New Zealand White rabbits (body weight ~3 kg, n= 75) by the explant method and were cultured in a humidified atmosphere (5% CO2/95% air) at 37°C (19, 22) . After 3-4 weeks, the tissue blocks were removed and the migrated VSMCs were cultured, followed by subculture with trypsinization. The identity of the VSMCs was confirmed by morphological examination and by staining for α-actin.
DNA Synthesis
DNA synthesis was examined by measurement of [ 3 H]thymidine incorporation into the cellular DNA as described previously (19, 22) . VSMCs at passage 1 or 2 were seeded in tissue culture plates 35 mm in diameter and grown to semi-confluence in Dulbecco's modified Eagle's medium (DMEM) con-taining 10% fetal bovine serum (FBS). Then, the medium was replaced with 2 ml of DMEM containing 0.1% FBS and incubated for ~72 h for growth arrest. Subsequently, the medium was replaced with DMEM containing 500 μg/ml bovine serum albumin, 10 μg/ml bovine insulin, 20 μg/ml human transferrin, and 25 ng/ml selenium (serum-free medium). Three different experiments were then performed, as outlined below.
1) Experiment 1: VSMCs were incubated with the indicated concentrations of U-II with native LDL, mox-LDL, ox-LDL, H2O2, LPC, or HNE for 48 h.
2) Experiment 2: VSMCs were incubated with the indicated concentrations of U-II, ET-1, Ang-II, 5-HT, or TX-A2 with mox-LDL or H2O2 for 48 h.
3) Experiment 3: VSMCs were incubated with the indicated concentrations of U-II, mox-LDL, or both along with an anti-Gq/11α antibody (2.5 μl/plate of 2 ml), a G protein inactivator (GDP-β-S, 100 μmol/l), an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor (erbstatin A, 10 μmol/l), a c-Src tyrosine kinase inhibitor (radicicol, 10 μmol/l), a protein kinase C (PKC) inhibitor (Ro31-8220, 0.1 μmol/l), an extracellular signal-regulated kinase (ERK) kinase inhibitor (PD98059, 10 μmol/l), a c-Jun N-terminal kinase (JNK) inhibitor (SP600125, 10 μmol/l), a Rho kinase (ROCK) inhibitor (Y27632, 10 μmol/l), a free radical scavenger (catalase, 10 U/ml), an intracellular antioxidant (NAC, 400 μmol/l), a cholesterol-lowering drug with potent antioxidant properties (probucol, 10 μmol/l), or an nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor (DPI, 1 μmol/l) for 48 h.
To ensure that the blocking activity of the inhibitors was not due to their cytotoxic effect, dose-response studies using inhibitors alone were carried out. From these studies, we selected a concentration that could be attained physiologically if the compound was not cytotoxic or a concentration that was at least 1 log below the cytotoxic concentration. For all 3 experiments, VSMCs were exposed to [ 3 H]thymidine at a concentration of 1 μCi/plate for the last 5 h during the 48 h incubation period and [ 3 H]thymidine incorporation into VSMC DNA was measured with a liquid scintillation counter (Packard Instrument Co., Downers Grove, USA). All of the experiments were performed in quadruplicate, and each experiment was repeated a minimum of 3 times.
Cell Number
Primary VSMCs at passage 1 or 2 were seeded in tissue culture plates 35 mm in diameter at a density of ~100,000 cells/ plate in DMEM containing 10% FBS (19, 22) . After 96 h, the growth medium was replaced with 2 ml of DMEM containing 0.1% FBS and incubated for ~72 h for growth arrest and synchronization. Then, the medium was replaced with serumfree medium and the indicated concentrations of U-II and mox-LDL and incubated for 48 h. The experiment was terminated by aspiration of the medium, and then plates were washed with PBS followed by addition of 1 ml of 2% (w/v) crude pancreatic trypsin in phosphate-buffered saline containing 152 mmol/l EDTA to each dish. The dishes were incubated at room temperature for 5 min. The contents of each dish were diluted to 10 ml with isotone II and the cell number was determined with an electronic cell counter (Coulter Corp., Hialeah, USA). Counting was performed in triplicate in each of the four plates and each experiment was repeated at least three times.
Statistical Analysis
All values are expressed as the means±SEM. Multiple comparisons were performed by 2-way analysis of variance combined with Bonferroni's post-hoc test to evaluate the synergistic interactions between the two factors. To assess the dose-dependent effect of U-II and the inhibitory effects of several inhibitors, Dunnett's test was used. A value of p< 0.05 was considered statistically significant.
Results
Effects of U-II and Other Vasoactive Agents on VSMC DNA Synthesis
As shown in 
Interactions of Mox-LDL, Ox-LDL, and Their Oxidative Components with U-II in Inducing VSMC DNA Synthesis
Low concentrations of mox-LDL (0.5 μg/ml), ox-LDL (0.5 μg/ml), H2O2 (5 μmol/l), LPC (5 μmol/l), or HNE (1 μmol/l), but not native LDL (0.5 μg/ml), added alone induced slight but significant increases in [ 3 H]thymidine incorporation (Fig.  2) . When added concomitantly, U-II even at a non-mitogenic concentration (10 nmol/l) significantly potentiated the effects of native LDL, mox-LDL, ox-LDL, H2O2, LPC, or HNE on [ 3 H]thymidine incorporation (Fig. 2) .
Interactions of Mox-LDL with U-II and Other Vasoactive Agents in Inducing VSMC DNA Synthesis
At low concentrations, mox-LDL (0.1 μg/ml) or U-II (10 nmol/l) alone did not significantly increase [ 3 H]thymidine incorporation (Fig. 3) . However, ET-1 (1 nmol/l), Ang-II (0.5 μmol/l), 5-HT (1 μmol/l), or TX-A2 (0.5 μmol/l) alone induced significant increases in [ 3 H]thymidine incorporation (Fig. 3) . When added concomitantly, even the non-mitogenic concentration of mox-LDL acted synergistically with U-II, ET-1, Ang-II, 5-HT, or TX-A2 in inducing [ 3 H]thymidine incorporation (all p< 0.0001) (Fig. 3) . 
Interactions of H2O2 with U-II and Other Vasoactive Agents in Inducing VSMC DNA Synthesis
We repeated the experiments to examine whether H2O2 (ROS donor) could mimic the mox-LDL-potentiated effects of U-II and the other vasoactive agents on [
3 H]thymidine incorporation. As shown in Fig. 4 , the combination of a low concentration of H2O2 (1 μmol/l) with U-II (10 nmol/l), ET-1 (1 nmol/l), Ang-II (0.5 μmol/l), 5-HT (1 μmol/l), or TX-A2 (0.5 μmol/l) also exerted synergism in inducing [ 3 H]thymidine incorporation (all p< 0.0001) (Fig. 4) .
Effects of U-II with Mox-LDL on VSMC Number
The effects of U-II and/or mox-LDL on VSMC number are shown in Fig. 5 . U-II (10 nmol/l) or mox-LDL (0.1 μg/ml) significantly increased the cell number (both p< 0.05 vs. the baseline value). When the two were added together, there was an additional increase in cell number compared with the single additions (p< 0.0001). The increase in VSMC number paralleled the increase in [
3 H]thymidine incorporation into DNA described above.
Inhibition of Mox-LDL-or U-II-Induced VSMC DNA Synthesis by Antioxidants or Signal Transduction Pathway Inhibitors
To determine how mox-LDL (5 μg/ml) exerts its mitogenic effect, we assessed the effects of the free radical scavenger, catalase, the intracellular antioxidant, NAC, the cholesterollowering drug with potent antioxidant properties, probucol, the NADPH oxidase inhibitor, DPI, or the JNK inhibitor, SP600125, on mox-LDL-induced [ 3 H]thymidine incorporation. To elucidate the intracellular signal transduction pathway of U-II (50 nmol/l), we assessed the effects of the G protein inactivator, GDP-β-S, the c-Src tyrosine kinase inhibitor, radicicol, the PKC inhibitor, Ro31-8220, the ERK inhibitor, PD98059, or the ROCK inhibitor, Y27632, on U-IIinduced [ 3 H]thymidine incorporation. Although catalase (10 U/ml), NAC (400 μmol/l), probucol (10 μmol/l), DPI (1 μmol/l), or SP600125 (10 μmol/l) alone had no significant effect on [ 3 H]thymidine incorporation (data not shown), these antioxidants significantly inhibited mox-LDL-induced [ 3 H]thymidine incorporation (Fig. 6) . Similarly, GDP-β-S (100 μmol/l), radicicol (10 μmol/l), Ro31-8220 (0.1 μmol/l), PD98059 (10 μmol/l), or Y27632 (10 μmol/l) alone showed no significant effect on [ 3 H]thymidine incorporation (data not shown), but these inhibitors significantly inhibited U-IIinduced [ 3 H]thymidine incorporation (Fig. 6) .
Inhibition of the Interaction between U-II and Mox-LDL in Inducing VSMC DNA Synthesis by Signal Transduction Pathway Inhibitors
To determine how U-II and mox-LDL exert their synergistic interaction, we assessed the effects of anti-Gq/11α antibody, an EGF receptor tyrosine kinase inhibitor (erbstatin A), a cSrc tyrosine kinase inhibitor (radicicol), a PKC inhibitor (Ro31-8220), an ERK inhibitor (PD98059), a JNK inhibitor (SP600125), or a ROCK inhibitor (Y27632) on the interaction between U-II and mox-LDL in inducing [ 3 H]thymidine incorporation. Anti-Gq/11α antibody (2.5 μl/plate of 2 ml), erbstatin A (10 μmol/l), radicicol (10 μmol/l), Ro31-8220 (0.1 μmol/l), PD98059 (10 μmol/l), SP600125 (10 μmol/l), or Y27632 (10 μmol/l) alone showed no significant effect on [ 3 H]thymidine incorporation (data not shown). As shown in Fig. 7 , anti-Gq/11α antibody, erbstatin A, SP600125, or Y27632 partially inhibited the synergistic interaction between U-II (10 nmol/l) and mox-LDL (0.1 μg/ml) (p< 0.05, p< 0.05, p< 0.005, respectively), whereas radicicol, Ro31-8220, or PD98059 completely abolished the synergistic interaction between the two (all p< 0.0001).
Fig. 6. Inhibition of mox-LDL-or U-II-induced VSMC DNA synthesis by antioxidants or signal transduction pathway inhibitors. Growth-arrested VSMCs were stimulated with mox-LDL (5 μg/ml) or U-II (50 nmol/l) in the presence or absence of catalase (10 U/ml), NAC (400 μmol/l), probucol (10 μmol/l), DPI (1 μmol/l), SP600125 (10 μmol/l), GDP-β-S (100 μmol/l), radicicol (10 μmol/l), Ro31-8220 (0.1 μmol/l), PD98059 (10 μmol/l), or Y27632 (10 μmol/l). The amount of [ 3 H]thymidine incorporation was measured. Data are shown as the mean±SEM (n= 10). Control value (242±12 cpm
)
Discussion
In the present study, when primary rabbit VSMCs were incubated with U-II or other vasoactive agents (ET-1, Ang-II, 5-HT, and TX-A2) in the presence or absence of mox-LDL or H2O2, the combinations of U-II and mox-LDL or U-II and H2O2 induced the highest level of DNA synthesis. This is the first evidence of the synergism of these combinations, and the most important finding of this study. The present study also demonstrated that the mechanisms underlying the synergistic interaction between U-II and mox-LDL were the interactions between U-II and the major oxidative components of mox-LDL (LPC, HNE, ROS), as well as multiple intracellular signal transduction pathways involved in the induction of VSMC DNA synthesis. However, further studies are required to demonstrate that these interesting phenomena would occur in primary human VSMCs, which is a limitation of the present study. Evidence reported by Douglas and colleagues has indicated that U-II is an important contributor to cardiovascular diseases (2, (4) (5) (6) 25) . U-II is the most potent vasoconstrictor identified to date, with 10-fold and 300-fold greater potency 
Fig. 8. Oxidative components of mox-LDL and ox-LDL. ROS, reactive oxygen species; LPC, lysophosphatidylcholine; HNE, 4-hydroxy-2-nonenal.
than ET-1 and norepinephrine, respectively (26) . U-II causes vasoconstriction in human coronary, pulmonary, mammary, and radial arteries, and saphenous and umbilical veins in vitro (26, 27) . Infusion of U-II into the forearm brachial artery has been shown to cause vasoconstriction in healthy volunteers (28) , and this effect was augmented in patients with essential hypertension (29) . Cheung et al. (10) showed that plasma concentrations of U-II were elevated in hypertensive patients as compared with normotensive controls and were positively correlated with systolic and diastolic blood pressures (10) . Their study showed that plasma concentrations of U-II are positively correlated with body weight and fasting plasma glucose level (10) . U-II is known to be present at high levels in the plasma of diabetic patients (14) and to inhibit glucoseinduced insulin release from pancreatic β cells, creating a predisposition to diabetes (30) . In addition to diabetes, U-II may also be associated with obesity (31) . Intracerebroventricular injection of U-II caused an increase in food and water intake in mice (32) . U-II has been shown to stimulate hyperlipidemia by increasing plasma concentrations of free fatty acids in coho salmon (33) . These findings suggest that U-II may be associated with the pathogenesis of the metabolic syndrome. Further studies using several selective UT receptor antagonists or urotensin converting enzyme inhibitor(s), and UT receptor-derived transgenic animals are required to investigate the precise roles of U-II in pathological conditions such as hypertension, atherosclerosis, and the metabolic syndrome.
Human U-II-like immunoreactivity in the human vasculature was first observed as diffuse staining in cardiac myocytes and intense staining in the macrophage-and VSMC-rich regions of human coronary atherosclerotic plaque (5). Hassan and colleagues (34) reported that U-II was expressed in endothelial cells, foam cells, and myointimal and medial VSMCs of atherosclerotic human coronary arteries. In contrast, Maguire and Davenport (1) reported the expression of U-II in endothelial cells of the human aorta and epicardial coronary artery as well as in intramyocardial vessels with diameters typical of resistance arteries (60-120 μm) but not in cardiac myocytes or VSMCs. However, UT receptors are present in VSMCs throughout the human coronary artery tree, from large epicardial to small resistance arteries, and mediate vasoconstriction (27) . In atherosclerotic lesions of the human coronary arteries, U-II was detected within the region of infiltrating macrophages of the plaque but not in contractile VSMCs of media or proliferated VSMCs of the thickened intima (1, 3) . Double immunostaining with anti-U-II antibody and an anti-CD68 antibody specific for macrophages demonstrated the co-localization of U-II and macrophages, suggesting that U-II may be produced mainly by these cells (3). Bousette and colleagues have recently shown that lymphocytes are by far the largest producers of U-II, whereas monocytes and macrophages are the largest producers of UT receptors, and that there is relatively little expression of UT receptors in foam cells, lymphocytes, or platelets in human blood (4) . Recent studies from our laboratory and by other groups have shown that U-II accelerates foam cell formation by up-regulating the expression of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-derived macrophages (35) , stimulates cell proliferation and up-regulates the expression of type 1 collagen in human endothelial cells (36, 37) , and activates NADPH oxidase and plasminogen activator inhibitor-1 in human VSMCs (38) , leading to atherosclerotic plaque formation. The expression of UT receptors is up-regulated by ox-LDL (39) as well as by hypoxia (40) and by the production of interferon-γ from activated T lymphocytes found within the atherosclerotic plaque (41) . In the present study, it is possible that mox-LDL may have increased UT receptor expression, thereby contributing to the synergistic interaction between mox-LDL and U-II in inducing VSMC proliferation.
It is well established that ox-LDL, which accumulates in vascular lesions, alters vascular cell function in ways that can be construed as atherogenic. LDL oxidation is a progressive process initially leading to the formation of mox-LDL and later to ox-LDL (22) . The extent of oxidation in LDL particles is dependent on the pro-oxidant conditions and the duration of oxidation (22) . Because plasma contains various natural antioxidants, extensive oxidation of LDL is unlikely to occur. Instead, LDL oxidation in the plasma may result in production of mox-LDL, which is the most potent of the three forms of LDL (19) . The increased mitogenic effect of mox-LDL or ox-LDL is attributable to the chemical changes brought about by oxidation of the components of LDL, i.e., generation of lipid peroxides and ROS and conversion of phosphatidylcholine (PC) to LPC (20) . As shown in Fig. 8 , during the early stages of oxidation of LDL, there is significant accumulation of peroxides and other ROS, whereas the LPC levels are still relatively low. After 24 h of oxidative stress, LDL contains large amounts of LPC but only small amounts of ROS. More or less at the same time, unsaturated aldehydes, such as HNE, are generated by β-scission of alkoxyl radicals in polyunsaturated fatty acids that are present in LDL. Extensive oxidation is associated with the formation of HNE (42) .
Several studies in our laboratory and by other groups have shown that mox-LDL and ox-LDL and their oxidative components, i.e., ROS (H2O2), LPC, and HNE, induce VSMC proliferation via the NADPH-dependent redox-sensitive JNK pathway as well as the ERK1/2 pathway (42-49). All mitogenic effects of U-II, ET-1, Ang-II, 5-HT, and TX-A2 on VSMCs are predominantly mediated via their specific G protein-coupled receptors (UT, ETA, AT1, 5-HT2A, or TP, respectively), c-Src tyrosine kinase, PKC, and the ERK pathway. In addition to the ERK pathway, U-II and other vasoactive agents activate the RhoA/ROCK-dependent pathway (50, 51) , ET-1 and TX-A2 activate the JNK pathway (52) (53) (54) , and Ang-II activates the JNK pathway and Janus kinase-2 (JAK-2)/signal transducer and activator of transcription-3 (STAT-3) pathway for VSMC proliferation (55, 56) . Therefore, it is possible that activation of multiple signal transduction pathways as described above may contribute to the synergistic interaction of mox-LDL or H2O2 with vasoactive agents in inducing VSMC proliferation.
In the present study, the synergistic interaction between U-II and mox-LDL was completely abolished by the c-Srctyrosine kinase inhibitor (radicicol), the PKC inhibitor (Ro31-8220), or the ERK kinase inhibitor (PD98059), and was partially inhibited by anti-Gq/11α antibody, the EGF receptor tyrosine kinase inhibitor (erbstatin A), the JNK inhibitor (SP600125), or the ROCK inhibitor (Y27632). This suggests that the c-Src/PKC/ERK pathway may be the common pathway for U-II and mox-LDL, and that the Gq protein, EGF receptor tyrosine kinase, JNK, or Rho A/ROCK pathways may be additional pathways for U-II and/or mox-LDL (Fig.  9) . Simultaneous activation of these multiple pathways may explain the underlying mechanism of synergistic interactions between the two agents. However, this has raised several questions. One is whether such a low concentration of U-II (10 nmol/l) or mox-LDL (0.1 μg/ml) could activate the ERK or JNK pathway. Tamura et al. (57) have shown that U-II at 10 nmol/l significantly increases the ERK phosphorylation in VSMCs. We demonstrated that the mitogenic effect of mox-LDL at 0.1 μg/ml is mediated via the redox-sensitive JNK pathway by using the specific inhibitors for JNK (SP600125) or NADPH oxidase (DPI) (125±10 to 97 ±6, 95±2; each p< 0.05) (58) . Another is whether the combination of higher concentrations of these two agents could induce more potent interactions. In our previous study (23) , the combination of higher concentrations of U-II and mox-LDL attenuated their synergistic interaction. Wang et al. (39) have recently shown that increasing concentrations of ox-LDL in combination with U-II down-regulate UT receptors and induce apoptosis in VSMCs.
There is increasing data for clarifying the interaction between classical growth factors and ox-LDL in modulating VSMC growth. Auge et al. (59) reported that ox-LDLinduced VSMC proliferation involved the EGF receptor/ phosphatidylinositol-3 kinase/Akt and the sphingolipid signaling pathways. Previous studies have shown that plateletderived growth factor-BB (PDGF-BB), EGF, basic fibroblast growth factor (FGF-2), or insulin-like growth factor (IGF) exerts a synergistic interaction with LDL in inducing VSMC proliferation (60) . However, recent studies showed that acidic FGF (FGF-1) interacts with ox-LDL to inhibit VSMC growth by formation of the FGF-1/ox-LDL complex, which has a dramatically decreased ability to bind heparin (61, 62) .
In conclusion, the results of the present study suggested that U-II shows synergistic interactions with mox-LDL in inducing VSMC proliferation at the greatest rate among the vasoactive agents. Activation of the Gq protein/tyrosine kinase/PKC/ERK and Rho A/ROCK pathways by U-II together with the redox-sensitive JNK pathway by mox-LDL may explain the synergistic interaction between the two agents. These synergistic interactions of several vasoactive agents, including U-II, with mox-LDL or H2O2 may explain the molecular mechanisms underlying the long-standing clinical observation that coexistence of hypertension with oxidative stress or hypercholesterolemia promotes the development of atherosclerosis and restenosis after angioplasty.
